← Back to headlines
Kiniksa Pharmaceuticals Forecasts $900M–$920M ARCALYST Revenue for 2026
Kiniksa Pharmaceuticals has provided guidance for its ARCALYST revenue in 2026, expecting it to be between $900 million and $920 million as the company deepens its market penetration.
24 Feb, 16:19 — 24 Feb, 16:19
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Global summit at IIT Kharagpur focuses on collaborative prosperity
16m ago
China boss offers US$26 million bonus; staff can take as many bills as possible within set time
17m ago
Apple Hospitality Outlines Flat RevPAR Guidance for 2026
18m ago
First Solar forecasts 2026 sales up to $5.2B as CuRe and perovskite tech ramp, eyes $2.6B–$2.8B EBITDA
18m ago